中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2014年
5期
860-861,863
,共3页
齐卫斌%魏志素%郭秀霞%王素敏%胡亚芳
齊衛斌%魏誌素%郭秀霞%王素敏%鬍亞芳
제위빈%위지소%곽수하%왕소민%호아방
早产儿%生长激素%临床效果
早產兒%生長激素%臨床效果
조산인%생장격소%림상효과
Preterm children%Growth hormone%Clinical effects
目的：：对比分析早产儿应用生长激素的临床效果。方法：随机将分娩的早产儿分为治疗组和对照组。对照组早产儿采取如吸氧、静脉输液、保温箱保温等不同的治疗方法；治疗组在对照组的基础上加用重组人生长激素。依据不同的目标方法检测指标变化,分析生长激素的临床疗效。结果：两组早产儿身高和身长比较,出生时的P>0.05(无统计学意义)；治疗组纠正胎龄后3月、6月、12月的体重与对照组比较,P<0.05(差异有统计学意义)；治疗组早产儿纠正胎龄后3月、6月、12月的身长与对照组比较,P<0.05(差异有统计学意义)。两组早产儿出生3天的血IGF-1水平,P>0.05(差异无统计学意义)；治疗组纠正胎龄3个月和6个月的血IGF-1水平与对照组比较,P<0.05(差异有统计学意义)。治疗组在使用重组人生长激素后,血糖均值为(5.34±1.74)mmol/L,与对照组的(4.52±1.41)mmol/L相比较,P<0.05(差异有统计学意义)。治疗组早产儿血中胰岛素水平、生长激素释放多肽水平、葡萄糖/胰岛素比值与对照组比较,P<0.05(差异有统计学意义)。结论：早产儿应用生长激素的临床效果好,有利于患儿的生长发育,临床治疗中可以推广使用。
目的：：對比分析早產兒應用生長激素的臨床效果。方法：隨機將分娩的早產兒分為治療組和對照組。對照組早產兒採取如吸氧、靜脈輸液、保溫箱保溫等不同的治療方法；治療組在對照組的基礎上加用重組人生長激素。依據不同的目標方法檢測指標變化,分析生長激素的臨床療效。結果：兩組早產兒身高和身長比較,齣生時的P>0.05(無統計學意義)；治療組糾正胎齡後3月、6月、12月的體重與對照組比較,P<0.05(差異有統計學意義)；治療組早產兒糾正胎齡後3月、6月、12月的身長與對照組比較,P<0.05(差異有統計學意義)。兩組早產兒齣生3天的血IGF-1水平,P>0.05(差異無統計學意義)；治療組糾正胎齡3箇月和6箇月的血IGF-1水平與對照組比較,P<0.05(差異有統計學意義)。治療組在使用重組人生長激素後,血糖均值為(5.34±1.74)mmol/L,與對照組的(4.52±1.41)mmol/L相比較,P<0.05(差異有統計學意義)。治療組早產兒血中胰島素水平、生長激素釋放多肽水平、葡萄糖/胰島素比值與對照組比較,P<0.05(差異有統計學意義)。結論：早產兒應用生長激素的臨床效果好,有利于患兒的生長髮育,臨床治療中可以推廣使用。
목적：：대비분석조산인응용생장격소적림상효과。방법：수궤장분면적조산인분위치료조화대조조。대조조조산인채취여흡양、정맥수액、보온상보온등불동적치료방법；치료조재대조조적기출상가용중조인생장격소。의거불동적목표방법검측지표변화,분석생장격소적림상료효。결과：량조조산인신고화신장비교,출생시적P>0.05(무통계학의의)；치료조규정태령후3월、6월、12월적체중여대조조비교,P<0.05(차이유통계학의의)；치료조조산인규정태령후3월、6월、12월적신장여대조조비교,P<0.05(차이유통계학의의)。량조조산인출생3천적혈IGF-1수평,P>0.05(차이무통계학의의)；치료조규정태령3개월화6개월적혈IGF-1수평여대조조비교,P<0.05(차이유통계학의의)。치료조재사용중조인생장격소후,혈당균치위(5.34±1.74)mmol/L,여대조조적(4.52±1.41)mmol/L상비교,P<0.05(차이유통계학의의)。치료조조산인혈중이도소수평、생장격소석방다태수평、포도당/이도소비치여대조조비교,P<0.05(차이유통계학의의)。결론：조산인응용생장격소적림상효과호,유리우환인적생장발육,림상치료중가이추엄사용。
Objective:To compare the therapeutic effect of growth hormone in application of preterm Infants.Methods:Random delivery of premature infants were divided into treatment group and control group. The control group of premature infants to take such as oxygen, intravenous infusion, insulation insulation, different methods of treatment;the treatment group in the control group based on the use of recombinant human growth hormone. According to the change of different methods of target detection index, analysis of clinical efficacy of growth hormone.Results:Comparison of two groups of preterm birth height and length, P>0.05 (not significant);treatment group corrected age of March, June, December weight compared with control group, P<0.05 (significant); group of corrected age of March, June, December and the body height compared to the control group treatment, P<0.05 (significant). Two groups of preterm birth blood IGF-1 level on day 3, P>0.05 (difference not significant);group blood IGF-1 levels in treatment group corrected age of 3 months and 6 months and the control, P<0.05 (significant). The treatment group in the use of recombinant human growth hormone, and mean blood glucose was (5.34 ± 1.74) mmol/L, and the control group (4.52 ± 1.41) mmol/L, P<0.05 (significant). The treatment group of blood insulin level, growth hormone releasing peptide level, glucose/insulin ratio compared with the control group, P<0.05 (significant). Conclusion:The clinical effect of application of growth hormone, is conducive to children's growth and development, can be widely used in clinical treatment.
